Lee Joon Woo, Moon Woo Kyung, Weinmann Hanns-Joachim, Kim Soo Jeoung, Kim Jong Hyo, Park Seong Ho, Kim Tae Jung, Yoon Chang Jin, Kim Young Hoon, Cho Eun Yoon, Ha Sung Whan, Kang Wee-Saing, Chang Kee Hyun
Department of Radiology and Clinical Research Institute, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.
Radiology. 2003 Oct;229(1):132-9. doi: 10.1148/radiol.2291020218.
To compare the magnetic resonance (MR) imaging enhancement patterns of a blood pool contrast agent, SH L 643A, with those of gadopentetate dimeglumine in postoperative scars and VX2 carcinomas in rabbits and to compare these enhancement patterns with microvessel density in pathologic specimens.
Eighteen rabbits with experimentally induced postoperative scars (n = 12) or VX2 carcinoma (n = 6) in the thighs underwent sequential MR imaging first with gadopentetate dimeglumine and then, 24 hours later, with SH L 643A. The enhancement ratios (ie, the ratios of postcontrast to precontrast signal intensity) and the microvessel densities of postoperative scars and VX2 carcinomas were assessed. Differences were tested for by using the Mann-Whitney U and Wilcoxon signed rank tests.
In postoperative scars, enhancement ratios were consistently lower with injection of SH L 643A than with injection of gadopentetate dimeglumine for up to 30 minutes (P <.05). In postoperative scars, mean peak enhancement ratios were 1.29 +/- 0.15 (SD) with injection of SH L 643A and 1.61 +/- 0.31 with injection of gadopentetate dimeglumine (P <.01). In VX2 carcinomas, the enhancement ratios were not significantly different with injection of SH L 643A than with injection of gadopentetate dimeglumine at all time points. The mean difference between the enhancement ratios of the VX2 carcinomas and postoperative scars was 0.64 +/- 0.10 (range, 0.50-0.77) with SH L 643A and 0.36 +/- 0.16 (range, 0.17-0.66) with gadopentetate dimeglumine (P <.01). The mean microvessel density (in terms of vessels per field of view) was 10.7 +/- 5.5 for postoperative scars and 30.0 +/- 7.7 for VX2 carcinoma (P <.001).
The difference between the enhancement ratios of postoperative scars and VX2 carcinomas with SH L 643A was greater than that with gadopentetate dimeglumine. Enhancement ratios at SH L 643A-enhanced MR imaging corresponded well with microvessel density in postoperative scars and VX2 carcinomas.
比较血池造影剂SH L 643A与钆喷酸葡胺在兔术后瘢痕和VX2癌中的磁共振(MR)成像增强模式,并将这些增强模式与病理标本中的微血管密度进行比较。
18只大腿上有实验性诱导术后瘢痕(n = 12)或VX2癌(n = 6)的兔,先接受钆喷酸葡胺的序列MR成像,然后在24小时后接受SH L 643A的成像。评估术后瘢痕和VX2癌的增强率(即对比剂注射后与注射前信号强度的比值)和微血管密度。使用Mann-Whitney U检验和Wilcoxon符号秩检验来检验差异。
在术后瘢痕中,注射SH L 643A后的增强率在长达30分钟内始终低于注射钆喷酸葡胺后的增强率(P <.05)。在术后瘢痕中,注射SH L 643A后的平均峰值增强率为1.29±0.15(标准差),注射钆喷酸葡胺后的为1.61±0.31(P <.01)。在VX2癌中,注射SH L 643A后的增强率在所有时间点与注射钆喷酸葡胺后的相比均无显著差异。使用SH L 643A时,VX2癌与术后瘢痕增强率的平均差异为0.64±0.10(范围为0.50 - 0.77),使用钆喷酸葡胺时为0.36±0.16(范围为0.17 - 0.66)(P <.01)。术后瘢痕的平均微血管密度(以每视野血管数计)为10.7±5.5,VX2癌为30.0±7.7(P <.001)。
SH L 643A使术后瘢痕和VX2癌的增强率差异大于钆喷酸葡胺。SH L 643A增强的MR成像中的增强率与术后瘢痕和VX2癌中的微血管密度良好对应。